Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 7.28 5.97% 0.41
PTLA closed up 5.97 percent on Monday, March 30, 2020, on 77 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Up
Historical PTLA trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 5.97%
1,2,3 Retracement Bearish Bearish Swing Setup 3.12%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.12%
Wide Bands Range Expansion 3.12%
NR7 Range Contraction 4.60%
NR7-2 Range Contraction 4.60%
Wide Bands Range Expansion 4.60%
NR7 Range Contraction 1.82%
Inside Day Range Contraction 1.82%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Clinical Medicine Surgery Inflammation Seattle Genetics Spinal Muscular Atrophy Inflammatory Disorders Thrombosis Astellas Pharma Anticoagulants Factor X Hematologic Disorders Portola Pharmaceuticals

Is PTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Mar 18 Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)
Mar 16 CLASS ACTION UPDATE for PTLA, GERN and CAN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Mar 16 Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
Mar 16 PORTOLA 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Portola Pharmaceuticals, Inc. - PTLA
Mar 15 SHAREHOLDER ALERT: PTLA BYND WBK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Mar 14 PORTOLA 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Portola Pharmaceuticals, Inc. - PTLA
Mar 13 PTLA Final Deadline Monday: Rosen, a Globally Recognized Firm, Reminds Portola Pharmaceuticals, Inc. Investors of Important March 16th Deadline in Securities Class Action – PTLA
Mar 13 SHAREHOLDER ALERT: PTLA WBK HPQ: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Mar 13 PTLA FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Portola Pharmaceuticals Inc. Investors With Losses Exceeding $100K of Class Action and Lead Deadline: March 16, 2020
Mar 12 The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PTLA, QD and AAN
See more PTLA news...

Indicators

Indicator Value
52 Week High 37.95
52 Week Low 5.31
Average Volume 1,576,155
200-Day Moving Average 23.12
50-Day Moving Average 10.99
20-Day Moving Average 7.73
10-Day Moving Average 6.85
Average True Range 0.89
ADX 58.41
+DI 11.50
-DI 29.15
Chandelier Exit (Long, 3 ATRs ) 7.65
Chandelier Exit (Short, 3 ATRs ) 7.98
Upper Bollinger Band 10.39
Lower Bollinger Band 5.07
Percent B (%b) 0.42
BandWidth 68.71
MACD Line -1.39
MACD Signal Line -1.65
MACD Histogram 0.262
Fundamentals Value
Market Cap 419.29 Million
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -1.60
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.24
Resistance 3 (R3) 8.15 7.75 8.08
Resistance 2 (R2) 7.75 7.50 7.79 8.03
Resistance 1 (R1) 7.51 7.35 7.63 7.60 7.97
Pivot Point 7.11 7.11 7.17 7.15 7.11
Support 1 (S1) 6.87 6.86 6.99 6.96 6.59
Support 2 (S2) 6.47 6.71 6.51 6.53
Support 3 (S3) 6.23 6.47 6.48
Support 4 (S4) 6.32